Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fludrocortisone Acetate

FDA-approved product (tablet, oral), marketed as Florinef, Fludrocortisone Acetate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Fludrocortisone Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adrenogenital syndrome
  • Chronic primary adrenal insufficiency
  • Primary adrenal insufficiency

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Mineralocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fludrocortisone Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fludrocortisone Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Androgen Reduction in Congenital Adrenal Hyperplasia

    NCT03548246 · start 2023-01

    Registered record
    Registry ID
    NCT03548246
    Conditions
    Congenital Adrenal Hyperplasia
    Interventions
    Abiraterone acetate; Placebo; Hydrocortisone; Fludrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2023-01
    Completion
    2026-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Adrenal Hyperplasia
    InterventionAbiraterone acetate; Placebo; Hydrocortisone; Fludrocortisone
    PhasePhase 2
    Registry statusWithdrawn

  • Effect of Pharmacological Interventions on Systolic Blood Pressure Drops (SynABPM 2 Proof-of-concept)

    NCT05729724 · start 2022-10-05

    Registered record
    Registry ID
    NCT05729724
    Conditions
    Syncope; Syncope, Vasovagal; Ambulatory Blood Pressure Monitoring; Antihypertensive Drugs; Orthostatic Hypotension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-10-05
    Completion
    2023-07-31
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSyncope; Syncope, Vasovagal; Ambulatory Blood Pressure Monitoring; Antihypertensive Drugs +1 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Paediatric Syncope in the Emergency Department

    NCT05555771 · start 2022-09-03

    Registered record
    Registry ID
    NCT05555771
    Conditions
    Syncope, Vasovagal; Postural Orthostatic Tachycardia Syndrome; Orthostatic Intolerance
    Interventions
    Counterpressure Maneuvers; Usual Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2022-09-03
    Completion
    2027-09-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSyncope, Vasovagal; Postural Orthostatic Tachycardia Syndrome; Orthostatic Intolerance
    InterventionCounterpressure Maneuvers; Usual Care
    PhaseNot applicable
    Registry statusRecruiting

  • Hemodynamics Effects of Fludrocortisone on the Pressor Response to Noradrenaline Septic Shock Patients

    NCT05001854 · start 2022-03-31

    Registered record
    Registry ID
    NCT05001854
    Conditions
    Septic Shock
    Interventions
    Fludrocortisone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Suspended
    Start
    2022-03-31
    Completion
    2024-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionFludrocortisone; Placebo
    PhasePhase 2 / Phase 3
    Registry statusSuspended

  • Hydrocortisone and Fludrocortisone for Critical Illness-related Corticosteroid Insufficiency

    NCT04404400 · start 2022-02-17

    Registered record
    Registry ID
    NCT04404400
    Conditions
    Critical Illness Related Corticosteroids Insufficiency
    Interventions
    Investigational products administration; Placebo administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-02-17
    Completion
    2026-02
    Enrolment
    1,092

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness Related Corticosteroids Insufficiency
    InterventionInvestigational products administration; Placebo administration
    PhasePhase 3
    Registry statusRecruiting

  • Mineralocorticoid Use in COVID-19 Patients

    NCT05453214 · start 2021-12-04

    Registered record
    Registry ID
    NCT05453214
    Conditions
    COVID-19; ARDS
    Interventions
    Fludrocortisone Acetate 0.1 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-12-04
    Completion
    2022-06-20
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19; ARDS
    InterventionFludrocortisone Acetate 0.1 MG
    PhasePhase 3
    Registry statusCompleted

  • Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage

    NCT04552873 · start 2020-12-03

    Registered record
    Registry ID
    NCT04552873
    Conditions
    Hyponatremia; Subarachnoid Hemorrhage; SIADH
    Interventions
    Urea; PLACEBO
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2020-12-03
    Completion
    2025-08-01
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyponatremia; Subarachnoid Hemorrhage; SIADH
    InterventionUrea; PLACEBO
    PhaseNot applicable
    Registry statusActive not recruiting

  • Midodrine and Fludrocortisone for Vasovagal Syncope

    NCT04595942 · start 2020-11-19

    Registered record
    Registry ID
    NCT04595942
    Conditions
    Syncope, Vasovagal
    Interventions
    Midodrine Hydrochloride Tablets; Fludrocortisone Acetate Tablets; Lifestyle modification
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-11-19
    Completion
    2023-12
    Enrolment
    1,375

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSyncope, Vasovagal
    InterventionMidodrine Hydrochloride Tablets; Fludrocortisone Acetate Tablets; Lifestyle modification
    PhasePhase 3
    Registry statusUnknown

  • Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension

    NCT04128137 · start 2020-07-09

    Registered record
    Registry ID
    NCT04128137
    Conditions
    Neurogenic Orthostatic Hypotension
    Interventions
    Fludrocortisone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-07-09
    Completion
    2024-06
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurogenic Orthostatic Hypotension
    InterventionFludrocortisone; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.

    NCT03773822 · start 2019-04-19

    Registered record
    Registry ID
    NCT03773822
    Conditions
    Cardiogenic Shock
    Interventions
    Hydrocortisone + Flucortac; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-04-19
    Completion
    2023-04-05
    Enrolment
    380

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiogenic Shock
    InterventionHydrocortisone + Flucortac; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

    NCT04351126 · start 2019-04-01

    Registered record
    Registry ID
    NCT04351126
    Conditions
    Ovarian Hyperstimulation Syndrome
    Interventions
    Fludrocortisone 0.1 Milligrams (mg); Bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-04-01
    Completion
    2020-02-29
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Hyperstimulation Syndrome
    InterventionFludrocortisone 0.1 Milligrams (mg); Bromocriptine
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of the Role of Hydrocortisone Either Alone or Combined With Fludrocortisone in the Outcome of Septic Shock in Adults

    NCT04492280 · start 2018-09-01

    Registered record
    Registry ID
    NCT04492280
    Conditions
    Septic Shock
    Interventions
    Hydrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-09-01
    Completion
    2019-09-01
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionHydrocortisone
    PhasePhase 4
    Registry statusCompleted

  • Salt Wasting, Hydro-sodium Balance and Fludrocortisone Requirement in Congenital Adrenal Hyperplasia

    NCT03550261 · start 2018-05-17

    Registered record
    Registry ID
    NCT03550261
    Conditions
    Congenital Adrenal Hyperplasia (CAH)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-05-17
    Completion
    2021-11-15
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Adrenal Hyperplasia (CAH)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

    NCT03436485 · start 2018-03-19

    Registered record
    Registry ID
    NCT03436485
    Conditions
    Prostate Cancer Metastatic
    Interventions
    ODM-208; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2018-03-19
    Completion
    2026-10-31
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    InterventionODM-208; Midazolam
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Diagnostic Accuracy of Seated Saline Suppression Test for Primary Aldosteronism

    NCT03500120 · start 2017-09-01

    Registered record
    Registry ID
    NCT03500120
    Conditions
    Primary Aldosteronism
    Interventions
    Seated saline infusion test
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-09-01
    Completion
    2019-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Aldosteronism
    InterventionSeated saline infusion test
    PhaseNot recorded
    Registry statusCompleted